Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-24C5 in CEACAM5-positive advanced solid tumors
NCT07387081Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-24C5 in solid tumor (advanced stage) (2 arms), sponsored by LaNova Medicines. Primary endpoint: Objective Response Rate at 110 weeks. Started Dec 2025; status: recruiting.
02
Drugs
LM-24C5
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07387081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387081.